Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

SECTION HEAD: Clinical/translational cancer immunotherapy BACKGROUND: The goal of this study was to estimate the objective response rate for utomilumab in adults with immune checkpoint inhibitor (ICI)-refractory melanoma and non–small-cell lung cancer (NSCLC). METHODS: Utomilumab was dosed intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Gopal, Ajay K., Shoushtari, Alexander N., Patel, Sandip P., He, Aiwu R., Doi, Toshihiko, Ramalingam, Suresh S., Patnaik, Amita, Sandhu, Shahneen, Chen, Ying, Davis, Craig B., Fisher, Timothy S., Huang, Bo, Fly, Kolette D., Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379324/
https://www.ncbi.nlm.nih.gov/pubmed/35983060
http://dx.doi.org/10.3389/fimmu.2022.897991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379324/
https://www.ncbi.nlm.nih.gov/pubmed/35983060
http://dx.doi.org/10.3389/fimmu.2022.897991

Ejemplares similares